文献速递儿科与产科急症

妊娠期宫内暴露丁丙诺啡联合纳洛酮与单用丁丙诺啡的安全性比较

Comparative Safety of In Utero Exposure to Buprenorphine Combined With Naloxone vs Buprenorphine Alone.
PubMed 文献 · JAMA · 2024-01-01
一句话结论妊娠早期暴露于丁丙诺啡联合纳洛酮与单用丁丙诺啡相比,新生儿和母亲结局相似,部分结局更有利,支持两种制剂均为妊娠期阿片类使用障碍的合理选择。

该研究基于美国2000至2018年医疗补助参保者数据,纳入妊娠早期暴露于丁丙诺啡联合纳洛酮的3369例孕妇和暴露于单用丁丙诺啡的5326例孕妇,比较围产期结局。结果显示,联合纳洛酮组新生儿戒断综合征风险较低(绝对风险37.4% vs 55.8%;加权RR 0.77,95%CI 0.70-0.84),新生儿重症监护入院风险(30.6% vs 34.9%;加权RR 0.91,95%CI 0.85-0.98)和小于胎龄儿风险(10.0% vs 12.4%;加权RR 0.86,95%CI 0.75-0.98)也略低。母亲发病率两组分别为2.6% vs 2.9%(加权RR 0.90,95%CI 0.68-1.19)。重大先天畸形、低出生体重、早产、呼吸症状或剖宫产方面未见差异。作者认为妊娠期使用丁丙诺啡联合纳洛酮似乎是安全的选择。

要点

  • 妊娠早期暴露于丁丙诺啡联合纳洛酮与单用丁丙诺啡相比,新生儿戒断综合征绝对风险37.4% vs 55.8%,加权RR 0.77(95%CI 0.70-0.84)。
  • 联合纳洛酮组新生儿重症监护入院风险略低(30.6% vs 34.9%;加权RR 0.91,95%CI 0.85-0.98)。
  • 联合纳洛酮组小于胎龄儿风险略低(10.0% vs 12.4%;加权RR 0.86,95%CI 0.75-0.98)。
  • 重大先天畸形、低出生体重、早产、呼吸症状或剖宫产方面两组未见差异。
  • 母亲发病率两组分别为2.6% vs 2.9%,加权RR 0.90(95%CI 0.68-1.19)。

适用人群与场景

  • 美国医疗补助参保的孕妇,妊娠前3个月至分娩后1个月有参保记录,且活产婴儿出生后前3个月有参保记录(除非死亡)。
  • 妊娠早期暴露于丁丙诺啡联合纳洛酮或单用丁丙诺啡(或早期从联合制剂转换为单用丁丙诺啡)的孕妇。

研究设计与关键结果

  • 研究类型:基于人群的队列研究,使用美国医疗补助参保者2000至2018年的医疗保健利用数据。
  • 暴露组:妊娠早期暴露于丁丙诺啡联合纳洛酮的孕妇3369例(平均[SD]年龄28.8[4.6]岁);对照组:暴露于单用丁丙诺啡或妊娠早期末转换为单用丁丙诺啡的孕妇5326例(平均[SD]年龄28.3[4.5]岁)。
  • 主要结局:新生儿戒断综合征绝对风险37.4% vs 55.8%,加权相对风险0.77(95%CI 0.70-0.84)。
  • 关键次要结局:新生儿重症监护入院绝对风险30.6% vs 34.9%,加权相对风险0.91(95%CI 0.85-0.98);小于胎龄儿绝对风险10.0% vs 12.4%,加权相对风险0.86(95%CI 0.75-0.98)。
  • 母亲发病率:2.6% vs 2.9%,加权相对风险0.90(95%CI 0.68-1.19)。
  • 重大先天畸形、低出生体重、早产、呼吸症状或剖宫产方面未见差异;敏感性分析结果一致。

证据类型、等级与局限

  • 证据类型:基于人群的队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对于所评估的结局,妊娠期使用丁丙诺啡联合纳洛酮与单用丁丙诺啡相比似乎是安全的选择。
  • 作者指出,这支持两种制剂均为妊娠期阿片类使用障碍的合理选择,肯定了协作治疗决策的灵活性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Buprenorphine combined with naloxone is commonly used to treat opioid use disorders outside of pregnancy. In pregnancy, buprenorphine alone is generally recommended because of limited perinatal safety data on the combination product.

OBJECTIVE: To compare perinatal outcomes following prenatal exposure to buprenorphine with naloxone vs buprenorphine alone.

DESIGN, SETTINGS, AND PARTICIPANTS: Population-based cohort study using health care utilization data from Medicaid-insured beneficiaries in the US from 2000 to 2018. The cohort was restricted to pregnant individuals linked to their liveborn infants, with maternal Medicaid enrollment from 3 months before pregnancy to 1 month after delivery and infant enrollment for the first 3 months after birth, unless they died sooner.

EXPOSURE: Use of buprenorphine with naloxone vs buprenorphine alone during the first trimester based on outpatient dispensings.

MAIN OUTCOMES AND MEASURES: Outcomes included major congenital malformations, low birth weight, neonatal abstinence syndrome, neonatal intensive care unit admission, preterm birth, respiratory symptoms, small for gestational age, cesarean delivery, and maternal morbidity. Confounder-adjusted risk ratios were calculated using propensity score overlap weights.

RESULTS: This study identified 3369 pregnant individuals exposed to buprenorphine with naloxone during the first trimester (mean [SD] age, 28.8 [4.6] years) and 5326 exposed to buprenorphine alone or who switched from the combination to buprenorphine alone by the end of the first trimester (mean [SD] age, 28.3 [4.5] years). When comparing buprenorphine combined with naloxone with buprenorphine alone, a lower risk for neonatal abstinence syndrome (absolute risk, 37.4% vs 55.8%; weighted relative risk, 0.77 [95% CI, 0.70-0.84]) and a modestly lower risk for neonatal intensive care unit admission (absolute risk, 30.6% vs 34.9%; weighted relative risk, 0.91 [95% CI, 0.85-0.98]) and small for gestational age (absolute risk, 10.0% vs 12.4%; weighted relative risk, 0.86 [95% CI, 0.75-0.98]) was observed. For maternal morbidity, the comparative rates were 2.6% vs 2.9%, respectively, and the weighted relative risk was 0.90 (95% CI, 0.68-1.19). No differences were observed with respect to major congenital malformations overall, low birth weight, preterm birth, respiratory symptoms, or cesarean delivery. Results were consistent across sensitivity analyses.

CONCLUSIONS AND RELEVANCE: There were similar and, in some instances, more favorable neonatal and maternal outcomes for pregnancies exposed to buprenorphine combined with naloxone compared with buprenorphine alone. For the outcomes assessed, compared with buprenorphine alone, buprenorphine with naloxone during pregnancy appears to be a safe treatment option. This supports the view that both formulations are reasonable options for the treatment of opioid use disorder in pregnancy, affirming flexibility in collaborative treatment decision-making.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Straub L, Bateman BT, Hernández-Díaz S, et al. Comparative Safety of In Utero Exposure to Buprenorphine Combined With Naloxone vs Buprenorphine Alone. JAMA. 2024. PMID: 39133511. doi:10.1001/jama.2024.11501

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。